eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Original paper

The effectiveness of omalizumab therapy in patients with chronic spontaneous urticaria: the experience of a single-centre study in Poland

Aleksandra Lesiak
1, 2
,
Natalia Bień
3
,
Klaudia Lipińska
3
,
Maria Rajczak
3
,
Małgorzata Skibińska
1
,
Justyna Ceryn
1
,
Dorota Sobolewska-Sztychny
1, 2
,
Irmina Olejniczak-Staruch
1
,
Joanna Narbutt
1

  1. Department of Dermatology, Paediatric Dermatology and Oncological Dermatology, Medical University of Lodz, Lodz, Poland
  2. Laboratory of Autoinflammatory, Genetic and Rare Skin Disorders, Medical University of Lodz, Lodz, Poland
  3. Student Scientific Research Club of Experimental, Clinical and Procedural Dermatology, Medical University of Lodz, Lodz, Poland
Adv Dermatol Allergol 2024; XLI (3): 301-305
DOI: https://doi.org/10.5114/ada.2024.141139
Online publish date: 2024/06/30
View full text Get citation
 
Introduction:
Omalizumab, which is a recombinant, humanised anti-immunoglobulin-E antibody, is the only approved drug for antihistamine refractory chronic spontaneous urticaria (CSU). It has been reported that it is an effective and safe drug, but the data about long-term effectiveness are still lacking.

Aim:
To perform a retrospective analysis of the patients with CSU treated with omalizumab at the dermatology department to assess effectiveness of omalizumab therapy in the single centre in Poland.

Material and methods:
A two-and-a-half-year retrospective analysis of patients with CSU undergoing the therapy with omalizumab was conducted. Patients’ data were analysed for many factors such as age, gender, severity indexes (UAS7, DLQI), duration and effects of the treatment used.

Results:
Sixty-one patients with CSU have been treated with omalizumab in the drug program. The number of female patients – 42 (68.9%) significantly dominated over the number of male patients – 19 (31.1%). The mean UAS7 during the first course of treatment declined from 33.2 to 2.8, during the second from 30.9 to 1.7 and during the third 32.7 to 2.5. In case of DLQI the mean scores decrease from 18 to 2.1 in the first cycle, from 16.9 to 1.9 in the second and from 18.6 to 1.1 in the third.

Conclusions:
Our study confirmed that omalizumab is an effective medicine in a long-term treatment which improves a physical as well as psychological condition of the patients with antihistamine-resistant CSU. To our knowledge, it is the first study in Poland that presents omalizumab effectiveness during three courses of treatment.

keywords:

omalizumab, chronic spontaneous urticaria, effectiveness, treatment
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.